RBDCOV | COVID-19 vaccine trials with immunocompromising conditions launched in Turkey

All the volunteers are adults affected by different pathologies or immunosuppressive conditions whose immune system may be less responsive to vaccines.

All the volunteers are adults affected by different pathologies or immunosuppressive conditions whose immune system may be less responsive to vaccines.
January 23, 2023

One of the objectives of the RBDCOV project is to test whether the vaccine can reactivate or re-generate a protective immune response to SARS-CoV-2 in immunocompetent and immunosuppressed individuals

Accordingly, within the RBDCOV project a clinical trial in Turkey for HIPRA’s COVID-19 vaccine in people with immunocompromising conditions has recently started, aiming at determining whether an additional dose of HIPRA’s COVID-19 vaccine can generate an immune response in people living with immune system disorders or who are receiving immunosuppressive treatments.

This study will determine if the vaccine is able to reactivate or re-generate a sufficient immune response and increase the activity of the immune system (natural defences) to SARS-CoV-2. Additionally, the safety of this new vaccine will be assessed, and it will be studied if it can prolong the effect of earlier vaccination that the participants have already received.

Asphalion is proud regulatory partner of RBDCOV by carrying out the regulatory pathway throughout the whole project by seeking scientific advice for the RBDCOV clinical trials with the European regulatory authorities, preparing the required documents to support clinical trial applications and supporting the preparation of the eCTD registration dossier currently under rolling review, among other regulatory activities.

For more details about the project, have a look at the project´s website: RBDCOV Project Website

For further information, you can contact us at: info@asphalion.com


Search News & Events

  • Filter by category


Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.


A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting